This activity is sponsored by

This activity is supported by an educational grant from

Hollie Devine, RN, MSN, CNP - Chair
Adult Nurse Practitioner–Board Certified
Educator for Advance Practice Nurses and Physician Assistants
Nursing Staff Development & Patient Education
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Bio

Kimberly A. Schmit-Pokorny, RN, MSN, OCN - Co-Chair
University of Nebraska Medical Center
Omaha, Nebraska

Bio

• Describe limitations of current stem cell mobilization techniques.
• Analyze novel stem cell mobilization strategies.
• Discuss ongoing clinical trial designs for incorporating stem cell mobilization agents.
• Identify patients at risk for poor stem cell mobilization.
• Develop treatment plans to maximize stem cells collected during apheresis.
• Discuss implications of current stem cell mobilization techniques on quality nursing care.

Target Audience
The target audience for Stem Cell Mobilization: Implications of Current Advances on Quality Nursing Management, includes key registered nursing leaders in stem cell transplantation.

Statement of Need
The first successful hematopoietic stem cell transplant (HSCT) attempt was reported more than 50 years ago. Today more than 50,000 autologous (auto-SCT) and allogeneic (allo-SCT) stem cell transplants are performed annually for both malignant and non-malignant hematological diseases. In the decades since that first report, advances in scientific understanding and process improvements in the transplant maneuver have resulted in increased numbers of long-term survivors and decreased adverse events.

Modifications of the graft composure and advances in how the product is obtained are among the many changes that have taken place. Current sources for HSCT grafts include bone marrow, peripheral blood stem cells (PBSC), and cord blood. Today, more than 90% of auto-SCT and 70% of allo-SCT in adults utilize a mobilized PBSC product. The quality of the mobilized stem cell product, currently measured by the quantity of CD34+ cells collected, remains a critical factor for engraftment. Further optimization of the PBSC mobilization process may further improve patient outcomes.

In the autologous setting, optimal methods for obtaining the targeted dose of stem cells in the most efficient manner for transplant represents a significant medical need. Furthermore, continuing clinical investigation in the allogeneic setting may demonstrate improved convenience for normal donors, and pharmacoeconomic analysis may indicate health-system cost savings. Healthcare professionals caring for HSCT patients and donors need to understand the basis for emerging therapeutic options, and the preclinical and clinical data supporting the development and integration of novel mobilization regimens into clinical practice. This live educational program will address optimal integration of emerging therapeutic strategies regarding stem cell mobilization, describe the means of optimizing stem cell mobilization while minimizing adverse events, and provide expert perspective of future directions in stem cell mobilization.

ACCREDITATION INFORMATION

NURSING CONTINUING EDUCATION
Postgraduate Institute for Medicine (PIM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 2.0 contact hours is provided by PIM.

FACULTY DISCLOSURE STATEMENT
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genzyme Corporation.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. During the period April 8, 2010 through April 7, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the activity and post-test by recording the best answer to each question.

A statement of credit will be issued only upon successful completion of the evaluation and post-test with a score of 70% or better. Your statement of credit will be made available online.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG, PIM, and Genzyme Corporation do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG, PIM, and Genzyme Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CME/CE INQUIRIES
For further information, please contact: Educational Concepts Group, LLC | 1300 Parkwood Circle SE | Suite 325 | Atlanta, Georgia 30339 | Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.